Free Trial

GSK (GSK) Competitors

GSK logo
$36.62 -0.34 (-0.91%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$36.50 -0.12 (-0.34%)
As of 02/21/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK vs. AZN, NVS, SNY, TAK, ARGX, BNTX, ONC, TEVA, SMMT, and GMAB

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Novartis (NVS), Sanofi (SNY), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

GSK vs.

GSK (NYSE:GSK) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.

GSK pays an annual dividend of $1.48 per share and has a dividend yield of 4.0%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.8%. GSK pays out 93.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 91.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$40.10B1.89$3.29B$1.5923.03
AstraZeneca$54.07B4.26$7.04B$2.2632.83

GSK presently has a consensus target price of $43.25, suggesting a potential upside of 18.09%. AstraZeneca has a consensus target price of $89.75, suggesting a potential upside of 20.96%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
3 Strong Buy rating(s)
2.60
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.10

15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GSK has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

In the previous week, AstraZeneca had 20 more articles in the media than GSK. MarketBeat recorded 56 mentions for AstraZeneca and 36 mentions for GSK. AstraZeneca's average media sentiment score of 0.42 beat GSK's score of 0.38 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
15 Very Positive mention(s)
5 Positive mention(s)
15 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AstraZeneca
28 Very Positive mention(s)
1 Positive mention(s)
22 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

GSK received 760 more outperform votes than AstraZeneca when rated by MarketBeat users. However, 59.62% of users gave AstraZeneca an outperform vote while only 57.12% of users gave GSK an outperform vote.

CompanyUnderperformOutperform
GSKOutperform Votes
822
57.12%
Underperform Votes
617
42.88%
AstraZenecaOutperform Votes
62
59.62%
Underperform Votes
42
40.38%

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.13%. GSK's return on equity of 48.59% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK8.13% 48.59% 11.11%
AstraZeneca 13.01%32.23%12.31%

Summary

AstraZeneca beats GSK on 15 of the 21 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$75.91B$7.04B$5.77B$20.07B
Dividend Yield4.04%2.87%4.78%3.65%
P/E Ratio23.036.1326.4634.90
Price / Sales1.89309.83453.2515.64
Price / Cash6.2567.8344.0420.85
Price / Book4.546.747.634.92
Net Income$3.29B$138.11M$3.18B$1.02B
7 Day Performance1.19%-2.43%-1.91%-1.05%
1 Month Performance9.53%-1.91%-0.19%-1.09%
1 Year Performance-13.13%-5.03%16.70%13.70%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
3.2617 of 5 stars
$36.62
-0.9%
$43.25
+18.1%
-12.7%$75.91B$40.10B23.0370,200Gap Down
AZN
AstraZeneca
2.4169 of 5 stars
$73.58
-1.2%
$89.75
+22.0%
+14.0%$228.18B$54.07B32.5689,900Options Volume
NVS
Novartis
3.018 of 5 stars
$105.43
-2.1%
$123.38
+17.0%
+6.7%$215.50B$50.32B17.9376,057Positive News
SNY
Sanofi
4.1298 of 5 stars
$54.50
+0.9%
$60.00
+10.1%
+13.6%$138.31B$44.46B21.8986,088Analyst Revision
Positive News
TAK
Takeda Pharmaceutical
2.5882 of 5 stars
$13.54
-0.6%
N/A-4.4%$43.07B$28.20B33.8449,281
ARGX
argenx
2.525 of 5 stars
$639.41
-1.8%
$658.39
+3.0%
+61.1%$38.85B$1.27B-726.601,148News Coverage
Positive News
BNTX
BioNTech
2.3788 of 5 stars
$119.83
-2.4%
$142.72
+19.1%
+29.4%$28.73B$4.13B-57.066,133Positive News
Gap Down
ONC
Beigene
N/A$230.86
+2.4%
N/AN/A$22.56B$2.46B-28.0210,600Insider Trade
News Coverage
Gap Up
TEVA
Teva Pharmaceutical Industries
2.891 of 5 stars
$16.24
-2.4%
$23.57
+45.2%
+28.8%$18.39B$16.54B-11.2037,851
SMMT
Summit Therapeutics
2.3033 of 5 stars
$21.37
-2.1%
$33.57
+57.1%
+438.2%$15.76B$700,000.00-76.32110Gap Up
GMAB
Genmab A/S
4.5899 of 5 stars
$21.30
+1.8%
$42.17
+98.0%
-22.8%$14.10B$2.39B20.682,204

Related Companies and Tools


This page (NYSE:GSK) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners